25.39 USD
+0.49 (+1.97%)
25.39 USD
0 (0%)
Overall XOMA gets a fundamental rating of 5 out of 10. We evaluated XOMA against 529 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMA while its profitability can be described as average. XOMA is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
XOMA had positive earnings in the past year.
XOMA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
In multiple years XOMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.75%, XOMA belongs to the top of the industry, outperforming 89.98% of the companies in the same industry.
XOMA has a better Return On Equity (9.14%) than 92.82% of its industry peers.
XOMA has a better Return On Invested Capital (3.31%) than 90.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROIC | 3.31% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 20.96%, XOMA belongs to the top of the industry, outperforming 93.95% of the companies in the same industry.
XOMA's Operating Margin of 20.92% is amongst the best of the industry. XOMA outperforms 95.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XOMA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XOMA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XOMA has more shares outstanding
The debt/assets ratio for XOMA is higher compared to a year ago.
2.2 Solvency
XOMA has an Altman-Z score of -4.59. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.59, XOMA is not doing good in the industry: 61.25% of the companies in the same industry are doing better.
XOMA has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMA is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.87, XOMA is not doing good in the industry: 75.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.59 |
ROIC/WACC0.37
WACC8.92%
2.3 Liquidity
A Current Ratio of 3.91 indicates that XOMA has no problem at all paying its short term obligations.
XOMA has a Current ratio (3.91) which is in line with its industry peers.
A Quick Ratio of 3.91 indicates that XOMA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.91, XOMA is in line with its industry, outperforming 48.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
XOMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.71%, which is quite impressive.
XOMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 103.96%.
Measured over the past years, XOMA shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
3.2 Future
Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
The Revenue is expected to grow by 34.85% on average over the next years. This is a very strong growth
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
XOMA is valuated quite expensively with a Price/Earnings ratio of 33.85.
XOMA's Price/Earnings ratio is rather cheap when compared to the industry. XOMA is cheaper than 92.44% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.38. XOMA is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 119.86 indicates a quite expensive valuation of XOMA.
88.66% of the companies in the same industry are more expensive than XOMA, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.83. XOMA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.85 | ||
| Fwd PE | 119.86 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XOMA is valued cheaper than 92.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.36 |
4.3 Compensation for Growth
XOMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y45.01%
EPS Next 3Y37.32%
5. Dividend
5.1 Amount
No dividends for XOMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
25.39
+0.49 (+1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.66%
Inst Owner Change1.89%
Ins Owners1.79%
Ins Owner Change7.06%
Market Cap314.33M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts82
Price Target72.08 (183.89%)
Short Float %3.01%
Short Ratio6.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)1.44%
PT rev (3m)1.44%
EPS NQ rev (1m)-127.67%
EPS NQ rev (3m)-127.67%
EPS NY rev (1m)100.31%
EPS NY rev (3m)204.67%
Revenue NQ rev (1m)-9.59%
Revenue NQ rev (3m)-9.59%
Revenue NY rev (1m)-6.18%
Revenue NY rev (3m)-6.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.85 | ||
| Fwd PE | 119.86 | ||
| P/S | 6.67 | ||
| P/FCF | N/A | ||
| P/OCF | 57.47 | ||
| P/B | 2.91 | ||
| P/tB | 4.96 | ||
| EV/EBITDA | 30.36 |
EPS(TTM)0.75
EY2.95%
EPS(NY)0.21
Fwd EY0.83%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.74%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.22
PEG (5Y)N/A
Graham Number12.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROCE | 4.2% | ||
| ROIC | 3.31% | ||
| ROICexc | 4.14% | ||
| ROICexgc | 5.42% | ||
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.77 | ||
| Cap/Depr | 880.03% | ||
| Cap/Sales | 42.84% | ||
| Interest Coverage | 0.83 | ||
| Cash Conversion | 45.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | -4.59 |
F-Score6
WACC8.92%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year158.48%
EBIT Next 3Y50.21%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you provide the ChartMill fundamental rating for XOMA ROYALTY CORPORATION?
ChartMill assigns a fundamental rating of 5 / 10 to XOMA.
Can you provide the valuation status for XOMA ROYALTY CORPORATION?
ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORPORATION (XOMA). This can be considered as Fairly Valued.
How profitable is XOMA ROYALTY CORPORATION (XOMA) stock?
XOMA ROYALTY CORPORATION (XOMA) has a profitability rating of 5 / 10.
What are the PE and PB ratios of XOMA ROYALTY CORPORATION (XOMA) stock?
The Price/Earnings (PE) ratio for XOMA ROYALTY CORPORATION (XOMA) is 33.85 and the Price/Book (PB) ratio is 2.91.
What is the expected EPS growth for XOMA ROYALTY CORPORATION (XOMA) stock?
The Earnings per Share (EPS) of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 153.81% in the next year.